TradeFlare's AI research teams analysed ABVX on 11 market nights between July 3, 2026 and August 18, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| August 18, 2026 | BUY | $120.73 | $138.39 / $103.73 | -0.8% | -14.1% | The stock is exhibiting a neutral technical setup, and while fundamentals and sentiment are bullish, the high risk score and lack of a clear technical entry point warrant a HOLD. |
| August 14, 2026 | BUY | $121.45 | — / — | -3.4% | -4.5% | The stock is currently in a neutral market regime and the risk score is high with only one bullish directional team. |
| August 13, 2026 | BUY | $125.52 | — / — | -2.7% | -2.3% | Positive Phase 3 trial results for obefazimod. |
| July 30, 2026 | BUY | $118.84 | — / — | +4.6% | -8.1% | Positive Phase 3 data for obefazimod in ulcerative colitis. |
| July 29, 2026 | BUY | $124.23 | — / — | +5.5% | -1.9% | Positive Phase 3 trial data for obefazimod. |
| July 27, 2026 | BUY | $125.70 | — / — | -2.5% | -9.3% | Positive news sentiment driven by a substantial funding round and strategic commercial leadership. |
| July 9, 2026 | HOLD | $138.54 | — / — | -2.1% | -7.6% | Positive Phase 3 trial results for obefazimod in ulcerative colitis. |
| July 8, 2026 | HOLD | $142.17 | — / — | -1.1% | -9.5% | Positive Phase 3 trial results for obefazimod. |
| July 7, 2026 | BUY | $144.65 | — / — | -5.1% | -11.9% | Positive Phase 3 trial data for obefazimod in ulcerative colitis. |
| July 6, 2026 | BUY | $144.65 | — / — | -5.6% | -13.3% | Positive Phase 3 trial data for obefazimod in ulcerative colitis. |
| July 3, 2026 | HOLD | $144.65 | — / — | -5.6% | -13.3% | Continued positive sentiment surrounding obefazimod's Phase 3 trial data. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.